Aerosol cosmetics

Abstract

To provide an aerosol cosmetic that has a high effect of promoting transdermal absorption and promoting blood flow. [Solution] An aerosol cosmetic comprising a stock solution containing microneedles and a propellant containing at least carbon dioxide, filled into an aerosol container equipped with a dispensing mechanism for dispensing the aerosol cosmetic, wherein the carbon dioxide concentration inside the aerosol container is 5,000 ppm or more. Preferably, the viscosity of the stock solution at 25°C is 500 mPa·s or more. Furthermore, it is preferable that the aerosol cosmetic be dispensed in the form of foam or drops.

Description

Technical Field

[0001] The present invention relates to an aerosol cosmetic containing microneedles.

Background Art

[0002] Conventionally, for the purpose of medical treatment and beauty, the act of applying or sticking drugs or useful components to the body to achieve transdermal absorption and obtain functional effects has been actively carried out. In particular, as transdermal absorbents for beauty purposes, ointments, cream preparations, tape preparations, etc. are often used. However, with these methods, it is difficult for useful components to penetrate the skin surface, and the expected functional effects are low. One of the reasons for the difficulty in skin penetration is the stratum corneum. The stratum corneum has a barrier function to prevent the entry of foreign substances from the outside. As long as this function is maintained soundly, it is difficult to absorb drugs or useful components into the body even when they are applied.

[0003] As one means of solving this problem, microneedles are being utilized. Microneedles are generally micro needles with a diameter of several hundred micrometers or less. When this needle pierces the skin, the useful components contained or applied to the needle can be supplied into the stratum corneum without being hindered by the barrier function. For example, in Patent Document 1, Patent Document 2, Patent Document 3, etc., attempts have been made to penetrate useful components into the skin using microneedles, and good results have been obtained. Since microneedles, which are extremely small, are less likely to cause pain or bleeding during insertion, they are easily used by general consumers for beauty purposes. Patent Documents 1 to 3 have achieved remarkable results in efficiently delivering useful components to the stratum corneum by utilizing microneedles. However, in recent years, even higher functional effects by transdermal absorption have been demanded.

Prior Art Documents

Patent Documents

[0004]

Patent Document 1

Patent Document 2

[0005] This invention has been made in view of the problems of the prior art described above, and aims to provide an aerosol cosmetic that has a high transdermal absorption promoting effect and a high blood flow promoting effect. [Means for solving the problem]

[0006] To solve the above problems, the aerosol cosmetic composition of the present invention is an aerosol cosmetic composition comprising a stock solution containing microneedles and a propellant containing at least carbon dioxide, which is filled into an aerosol container equipped with a dispensing mechanism for dispensing the aerosol cosmetic composition, and the carbon dioxide concentration (carbon dioxide concentration) inside the aerosol container is 5,000 ppm or more.

[0007] Preferably, the viscosity of the stock solution at 25°C is 500 mPa·s or higher.

[0008] The aerosol cosmetic composition is preferably dispensed in the form of foam or drops. [Effects of the Invention]

[0009] The present invention offers the remarkable advantage of providing an aerosol cosmetic that has a high transdermal absorption promoting effect and a high blood flow promoting effect. [Brief explanation of the drawing]

[0010] [Figure 1] This is a photograph showing the results of Reference Example 1. [Figure 2] This graph shows the results of Reference Example 1. [Figure 3] This is a photograph showing the results of Reference Example 2. [Figure 4]This graph shows the results of Reference Example 2. [Modes for carrying out the invention]

[0011] The embodiments of the present invention are described below, but these are illustrative examples, and it goes without saying that various modifications are possible as long as they do not deviate from the technical concept of the present invention.

[0012] The aerosol cosmetic composition of the present invention contains a stock solution containing microneedles and carbon dioxide. It is preferable that the aerosol cosmetic composition be filled into an aerosol container equipped with a dispensing mechanism for dispensing the aerosol cosmetic composition. It is preferable that the carbon dioxide concentration inside the aerosol container is 5,000 ppm or higher.

[0013] As the aforementioned microneedles, a wide range of known microneedles can be used. Microneedles generally refer to tiny needles with a diameter of several hundred micrometers or less. Conventionally, metal microneedles have been used as medical devices, but in recent years, microneedles made from a type of silica bone extracted from sponges or water-soluble materials such as hyaluronic acid that dissolves in water in the human body have been developed. In this invention, there are no particular restrictions on the material of the microneedles, but metal microneedles used as medical devices cause severe pain during use and require the use of anesthetics. Furthermore, there is a risk of infection due to bleeding, making it difficult for general consumers to use them at home. Microneedles made from sponges or water-soluble materials do not require anesthetics and do not cause bleeding, so they are readily used in the fields of cosmetics and beauty, and in this invention, microneedles made from sponges or water-soluble materials can be suitably used. In addition, biodegradable materials such as biodegradable resins and biodegradable polysaccharides can also be suitably used. Furthermore, microneedles containing active ingredients can also be suitably used. By using these microneedles, it is possible to stimulate the growth of new cells by pricking or damaging the skin, thereby revitalizing the skin, and to penetrate target substances such as whitening ingredients into the stratum corneum.

[0014] There are no particular restrictions on the shape of the microneedle, but a fine, needle-like shape is preferred. Furthermore, there are no particular restrictions on the size of the microneedles, but those in the range of 80 to 339 μm in length and 5 to 20 μm in diameter are preferred.

[0015] While there are no particular restrictions on the amount of microneedles present, it is preferable that the undiluted solution contains 0.01 to 2.00% by mass, and more preferably 0.1 to 1.0% by mass. By setting the microneedle content within this range, an aerosol product that provides a moderate level of stimulation during use can be provided.

[0016] In this invention, by discharging a stock solution containing microneedles from an aerosol container together with a propellant containing at least carbon dioxide, the microneedles penetrate the skin and disperse into the stratum corneum, and the carbon dioxide promotes blood circulation and transdermal absorption, thereby achieving a significantly higher effect than ordinary microneedle-containing cosmetics or ordinary aerosol cosmetics. In particular, the aerosol cosmetic of the present invention has an extremely high blood flow promoting effect, and after being dispensed onto the skin, it can cause erythema due to increased blood flow. Specifically, when the aerosol cosmetic is dispensed onto the skin, the carbon dioxide dissolved in the dispensed substance penetrates from the skin surface into the interior. The higher the concentration of carbon dioxide, the more the peripheral blood vessels tend to dilate and the blood flow increases. At this time, the skin appears red and exhibits erythema. This erythema is temporary, and once the supply of carbon dioxide is stopped, the increase in blood flow also subsides, and the erythema disappears. In the present invention, erythema that occurs after holding the carbon dioxide-containing dispensed substance on the skin for more than one minute disappears within 1 to 5 minutes after the dispensed substance is removed.

[0017] The propellant used in the aerosol cosmetic may be carbon dioxide alone, or a combination of carbon dioxide and other components, but the carbon dioxide content in the propellant is preferably 15 to 100% by mass, and more preferably 50 to 100% by mass. As the propellant component other than carbon dioxide gas, there is no particular limitation, and for example, liquefied gases such as LPG and compressed gases such as nitrogen gas are used.

[0018] The viscosity of the stock solution at 25°C is preferably 50 mPa·s or more, more preferably 500 mPa·s or more, still more preferably 1,000 mPa·s or more and 10,000 mPa·s or less, and even more preferably 1,500 mPa·s or more and 10,000 mPa·s or less. Also, from the viewpoint of workability, the viscosity is preferably 3,000 mPa·s or less. By setting the viscosity of the stock solution within the above range, it is possible to prevent clogging of the micro needle ejection mechanism during the ejection of the aerosol cosmetic, and further prevent dripping. In particular, by setting the viscosity of the stock solution within the above range, even if the content of the micro needle in the stock solution is increased, the micro needle will not clog the ejection mechanism during use, and the aerosol product can be comfortably used. Furthermore, by setting the viscosity within the above range, carbon dioxide gas can be effectively retained in the aerosol cosmetic, and the blood flow promoting effect can be further enhanced.

[0019] The stock solution may contain known additives and active ingredients contained in cosmetics. In particular, in order to set the viscosity of the stock solution within a suitable range, it is preferable to contain a viscosity modifier. Examples of the viscosity modifier include higher alcohols that are solid at normal temperature, fatty acids that are solid at normal temperature and their salts, water-soluble thickeners, oil-soluble thickeners, waxes and hydrocarbons that are solid at normal temperature, clay minerals, and the like. These viscosity modifiers may be used alone or in combination of two or more.

[0020] Examples of the higher alcohol that is solid at normal temperature include behenyl alcohol, cetyl alcohol, cetearyl alcohol, stearyl alcohol, hardened rapeseed oil alcohol, myristyl alcohol, arachidyl alcohol, coconut alcohol, and the like.

[0021] Examples of the room-temperature solid fatty acids and their salts include stearic acid, myristic acid, palmitic acid, lauric acid, behenic acid, etc., and their metal salts.

[0022] Examples of the water-soluble thickeners include xanthan gum, tamarind gum, guar gum, gum arabic, carrageenan, sodium alginate, locust bean gum, pectin, methylcellulose, propylcellulose, cellulose, cellulose nanofiber, hydroxyethylcellulose, cationized cellulose, guar hydroxypropyltrimonium, sclerotium gum, duran gum, Tremella fuciformis polysaccharides, polyacrylamide compounds, acrylic acid / alkyl methacrylate copolymers, acrylic acid / alkyl methacrylate copolymers, polyacrylic acid or its metal salts, nonionic film-forming vinyl polymers, hyaluronic acid or its metal salts, polyquaternium-7, and the like.

[0023] Examples of the oil-soluble thickeners include dextrin palmitate, glyceryl behenate, and glyceryl eicosanedioate.

[0024] Examples of the aforementioned room-temperature solid waxes and hydrocarbons include beeswax, carnauba wax, candelilla wax, lanolin, petrolatum, and microcrystalline wax.

[0025] Examples of the aforementioned clay minerals include bentonite, montmorillonite, disteardimonium hectorite, and hectorite.

[0026] The aerosol cosmetic composition of the present invention is preferably dispensed in the form of foam or drops. In the present invention, drop-shaped dispensing means that when the contents come out of the nozzle of the dispensing mechanism attached to the aerosol container, they are dispensed as a liquid rather than as a mist or foam, or that they are slightly foamed but have not yet reached the form of foam. Dispensing in the form of foam or drops allows the carbon dioxide contained in the undiluted solution to not volatilize as much as when dispensed as a mist, and by remaining on the skin along with the undiluted solution, it has the effect of promoting blood flow.

[0027] The diameter of the valve stem hole of the dispensing mechanism is preferably 0.4 mm or more, more preferably 0.4 to 0.6 mm, and even more preferably 0.5 to 0.6 mm. The valve stem hole is the hole through which the liquid contents pass when they exit the aerosol container, and is designed to open only when the dispensing button is pressed. By setting the diameter of the valve stem hole within the above range, clogging of the microneedle dispensing mechanism during the dispensing of aerosol cosmetics can be further prevented.

[0028] The carbon dioxide concentration inside the aerosol container is preferably 5,000 ppm or higher, and more preferably 10,000 ppm or higher. By setting the carbon dioxide concentration inside the aerosol container within the above range, a sufficient amount of the discharge can be applied to the skin, etc., and an excellent blood flow promoting effect can be achieved. For example, when a sufficient amount of the discharge is held on the skin for one minute, erythema due to improved blood flow is observed, demonstrating a significant blood flow promoting effect. [Examples]

[0029] The present invention will be described in more detail below with reference to examples, but it goes without saying that these examples are provided illustratively and should not be interpreted as limiting.

[0030] (Experimental Example 1) Evaluation of erythema and irritation using carbon dioxide and microneedles Stock solutions (stock solutions A1 to A4) were prepared according to the compositions (mixing amount: mass%) listed in Table 1 below, and the viscosity of the obtained stock solutions was measured using a B-type viscometer (measurement temperature: 25°C).

[0031] [Table 1]

[0032] Samples were prepared by mixing microneedles with stock solutions of various viscosities so that the amount of microneedles was 0.05 to 2.0% by mass relative to the stock solution. As microneedles, commercially available microneedles made from hydrolyzed sponges (product name: EC-Spicule (hydrolyzed sponge), sold by Future Cell Japan Co., Ltd., 100% by mass of hydrolyzed sponge, shape: needle-shaped, length: 80-140 μm) were used. Aerosol products were manufactured by filling an aerosol container (with a valve stem hole diameter of 0.5 mm) with the prepared sample and propellant (carbon dioxide only) according to the compositions shown in Tables 2 to 6 below, and then filling it with aerosol cosmetic. Carbon dioxide levels were measured using a GV-100S detector tube gas analyzer (manufactured by Gastec Co., Ltd.), a No. MRCO2 carbon dioxide detector tube (for use with carbonated hot water production equipment) (manufactured by Mitsubishi Rayon Co., Ltd.), and a 500 mL plastic container with a cap.

[0033] The following measurements were performed on the obtained aerosol products. The results of the erythema evaluation are shown in Tables 2-5, and the results of the irritation evaluation are shown in Table 6. <Erythema Assessment> As shown in Reference Example 1 below, there is a correlation between the presence or absence of erythema and increased blood flow. Since erythema is observed along with a significant increase in blood flow, the blood flow promoting effect was confirmed by evaluating erythema. Using the aerosol product obtained above, a sufficient amount (about the size of a ping-pong ball) of the aerosol cosmetic was dispensed onto the back of the hand, left to stand for 1 minute, then rinsed with running water, and the redness of the erythema was visually observed and evaluated on a 4-point scale (room temperature at the time of measurement: 25°C). Note that the skin erythema was not due to inflammation, etc., and the redness gradually disappeared when left alone, and the visual observation was performed immediately after rinsing. The evaluation criteria were based on the intensity of the erythema's redness on a 4-point scale: weak (1) → strong (4). The most frequent evaluation from the five subjects was adopted.

[0034] [Table 2]

[0035] [Table 3]

[0036] [Table 4]

[0037] [Table 5]

[0038] <Stimulus Evaluation> Using the aerosol product obtained above, a sufficient amount (about the size of a ping-pong ball) of the aerosol cosmetic was dispensed onto the back of the hands of five subjects, and the irritation felt when spreading it with the fingertips was evaluated. The most frequent rating from the five subjects was adopted. The evaluation criteria are as follows: Excessive irritation impairs the product's quality, so an irritation rating of 1 to 3 is considered a suitable range of appropriate irritation. Stimulus evaluation 0: No sensation felt. 1: I feel a slight tingling sensation. 2: I feel a tingling sensation. 3: I feel a strong sensation. 4. The stimulus is perceived as pain and is rejected.

[0039] [Table 6]

[0040] As shown in Tables 2-5, erythema was observed due to the inclusion of carbon dioxide. In particular, erythema of sufficient redness (evaluation 3 or higher) was observed at carbon dioxide concentrations of 5,000 ppm or higher. A viscosity range of 500 mPa·s or higher is more preferable, while 3,000 mPa·s or lower is preferable from the standpoint of workability. Furthermore, as shown in Table 6, while the inclusion of needles can cause irritation, excessive irritation impairs the product's quality. Therefore, an irritation rating of 1 to 3 is preferable, and a needle content of 0.1 to 1.0 wt% by mass ratio of the undiluted solution was particularly desirable.

[0041] (Examples 1 and 2 and Comparative Example 1) The stock solutions (stock solutions 1-3) were prepared according to the compositions (amount: mass%) listed in Table 7 below. As microneedles, commercially available microneedles made from hydrolyzed sponges (product name: EC-Spicule (hydrolyzed sponge), sold by Future Cell Japan Co., Ltd., hydrolyzed sponge 100% by mass, shape: needle-shaped, length: 80-140 μm) were used. The viscosity of the obtained stock solution was measured using a B-type viscometer (rotation speed 12 rpm), and the viscosity at 25°C was found to be 4000 mPa·s.

[0042] [Table 7]

[0043] An aerosol product was manufactured by filling an aerosol container (with a valve stem hole diameter of 0.5 mm) with the prepared stock solution and propellant (carbon dioxide only, or carbon dioxide + LPG) according to the composition shown in Table 8 below, and then filling it with aerosol cosmetic.

[0044] The following measurements were performed on the obtained aerosol products. <Evaluation test of blood circulation promotion effect> Using the aerosol product obtained above, an amount the size of a cherry (diameter: 15-20 mm) of the aerosol cosmetic was dispensed onto the inside of the forearm, held for 1 minute, and then rinsed off with water. The presence of erythema on the skin after rinsing with water was visually evaluated. The evaluation criteria are as follows. The results are shown in Table 8. The observed erythema disappeared within 5 minutes after the aerosol cosmetic was rinsed off with water. Erythema evaluation ×: No erythema (Erythema evaluation rating 1-2 above), △: Mild erythema present (Erythema evaluation rating 3 above), ○: Clear erythema present (Erythema evaluation rating 4 above).

[0045] [Table 8]

[0046] (Examples 1-2) The prepared stock solution 1 and propellant (carbon dioxide gas only, 22,000 ppm) were filled into the aerosol container, and an aerosol cosmetic was added to produce an aerosol product.

[0047] Erythema evaluation and severity evaluation were performed on the obtained aerosol products using the same method as in Experimental Example 1. The erythema evaluation result was 4, indicating that a strong reddish erythema was observed. The stimulus evaluation result was 1, indicating that only slight stimulation (within the appropriate stimulus range) was felt.

[0048] (Examples 3-5 and Comparative Example 2) Stock solutions (stock solutions 4-7) were prepared according to the compositions (amount: mass%) listed in Table 9 below. The same microneedles as in Example 1 were used. The viscosity of the obtained stock solutions was measured using the same method as in Example 1, and the viscosity at 25°C was 8500 mPa·s.

[0049] [Table 9]

[0050] An aerosol product was manufactured by filling an aerosol container (with a valve stem hole diameter of 0.5 mm) with the prepared stock solution and propellant (carbon dioxide) according to the composition shown in Table 10 below, and then filling it with aerosol cosmetic. The obtained aerosol product was subjected to an evaluation test of its blood circulation promoting effect using the same method as in Example 1. The results are shown in Table 10.

[0051] [Table 10]

[0052] (Examples 3-2, 4-2, 5-2) The prepared stock solutions 4 to 6 and a propellant (carbon dioxide only, 11,800 ppm) were filled into the aerosol container, and an aerosol cosmetic was added to produce an aerosol product (Example 3-2: stock solution 4, Example 4-2: stock solution 5, Example 5-2: stock solution 6).

[0053] Erythema and irritation evaluations were performed on the obtained aerosol products using the same method as in Experimental Example 1. The results are shown in Table 11. It is presumed that the irritation evaluation results in Table 11 are less pronounced than those in Table 6, due to the effects of oily formulations, etc.

[0054] [Table 11]

[0055] (Examples 6, 7 and Comparative Example 3) Stock solutions (stock solutions 8-10) were prepared according to the compositions (amount: mass%) listed in Table 12 below. The same microneedles as in Example 1 were used. The viscosity of the obtained stock solutions was measured using the same method as in Example 1, and the viscosity at 25°C was 1500 mPa·s.

[0056] [Table 12]

[0057] An aerosol product was manufactured by filling an aerosol container (with a valve stem hole diameter of 0.5 mm) with the prepared stock solution and propellant (carbon dioxide) according to the composition shown in Table 13 below, and then filling it with aerosol cosmetic. The obtained aerosol product was subjected to an evaluation test of its blood circulation promoting effect using the same method as in Example 1. The results are shown in Table 13.

[0058] [Table 13]

[0059] (Examples 6-2, 7-2) The prepared stock solutions 8 and 9 and a propellant (carbon dioxide only, 17,400 ppm) were filled into the aerosol container, and an aerosol cosmetic was added to produce an aerosol product (Example 6-2: Stock solution 8, Example 7-2: Stock solution 9).

[0060] Erythema and irritation evaluations were performed on the obtained aerosol products using the same method as in Experimental Example 1. The results are shown in Table 14. It is presumed that the irritation evaluation results in Table 14 are less severe than those in Table 6, due to the effects of oily formulations, etc.

[0061] [Table 14]

[0062] (Reference example 1) The prepared stock solution 10 and propellant [no propellant (stock solution as is), carbon dioxide gas only 10,000 ppm (1%) or 15,000 ppm (1.5%)] were filled into the aerosol container, and an aerosol cosmetic (beauty serum) was added to produce an aerosol product.

[0063] The obtained aerosol products were evaluated for erythema using the same method as in Experimental Example 1. No erythema was observed with no propellant (undiluted solution). With carbon dioxide at 10,000 ppm (1%) and 15,000 ppm (1.5%), the erythema evaluation result was 4, indicating that strong red erythema was observed.

[0064] The obtained aerosol products were subjected to an evaluation test of their blood flow promoting effect using laser Doppler blood flow measurement (blood flow visualization test) according to the method described below. Blood flow measurements were performed using the PeriScan PIM III laser Doppler blood flow imaging device [manufactured by Integral Co., Ltd.]. <Blood flow visualization test> The measurement area (approximately 1 cm square) was plotted on the inside of the forearm using an oil-based marker. Purified water was added to the plot area (for correction), left for 2 minutes, then the purified water was removed, and blood flow measurement <Measurement 1> was immediately started. After Measurement 1, the aerosol cosmetic was dispensed onto the plot area using the aerosol product, left for 2 minutes, the aerosol cosmetic was removed, and blood flow measurement <Measurement 2> was immediately started. The blood flow increase rate was calculated from the results of Measurement 1 and Measurement 2. The blood flow increase rate is calculated by dividing the blood flow rate within the plotted measurement range by the value per unit area and comparing the values ​​before and after application. An increase rate of 1 means that the change before and after application of the aerosol cosmetic is 0. The above measurements 1 and 2 were performed three times, and the average value of the blood flow increase rate was calculated.

[0065] Figure 1 shows a photograph illustrating the results of the blood flow distribution image, and Figure 2 shows a graph of the average rate of increase in blood flow. Table 15 shows the results of the t-test on the calculated average rate of increase in blood flow.

[0066] [Table 15]

[0067] As shown in Figure 1, in the aerosol cosmetic without propellant (undiluted solution), no red spots (areas with high blood flow) were observed, while in the aerosol product (filled with carbon dioxide) where strong redness and erythema were observed, a significant increase in red spots (areas with high blood flow, the dark areas in the center between 10,000 ppm and 15,000 ppm in Figure 1) was confirmed. Furthermore, as shown in Figure 2, a significant increase in blood flow after application of the aerosol cosmetic was confirmed, depending on the carbon dioxide concentration. Therefore, it was shown that there is a relationship between carbon dioxide concentration and blood flow, and that the presence of erythema indicates a significant increase in blood flow.

[0068] (Reference example 2) Stock solution 11 (lotion) was prepared according to the composition (amount: mass%) listed in Table 16 below. The viscosity of the obtained stock solution was measured using the same method as in Example 1, and the viscosity at 25°C was 50 mPa·s.

[0069] [Table 16]

[0070] The prepared stock solution 11 and propellant [no propellant (stock solution as is), carbon dioxide only 10,000 ppm (1%) or 15,000 ppm (1.5%)] were filled into the aerosol container, and an aerosol cosmetic (lotion) was added to produce an aerosol product.

[0071] The obtained aerosol products were evaluated for erythema using the same method as in Experimental Example 1. No erythema was observed under any of the conditions. The obtained aerosol products were subjected to an evaluation test of the blood flow promoting effect (blood flow visualization test) using laser Doppler blood flow measurement in the same manner as in Reference Example 1. The results are shown in Figures 3 and 4 and Table 17. As shown in Figures 3 and 4, a slight increase in blood flow was confirmed due to the effect of carbon dioxide (in the photograph in Figure 3, the area that was entirely blue in the 0 (undiluted solution) area shows a yellow to red area in the center in the 10,000 ppm and 15,000 ppm areas). As shown in the results of Reference Examples 1 and 2, the greater the carbon dioxide concentration, the greater the effect of increasing blood flow, and the longer the carbon dioxide remains in the aerosol cosmetic, the greater the effect of increasing blood flow. Therefore, from the standpoint of increasing blood flow, it is preferable for the aerosol cosmetic to have viscosity, and it is even more preferable for the viscosity of the undiluted solution at 25°C to be 500 mPa·s or higher.

[0072] [Table 17]

[0073] As shown in Experimental Example 1 and Examples 1-7 in Tables 1-14, the aerosol cosmetic of the present invention caused a moderate irritation and erythema due to improved blood flow, demonstrating an extremely high blood flow promoting effect. Furthermore, in Examples 1-7, all aerosol products containing carbon dioxide as a propellant were dispensed as foam or drops, and the carbon dioxide contained in the undiluted solution remained on the skin along with the solution, demonstrating an even greater effect in promoting blood flow. Therefore, the aerosol cosmetic composition of the present invention, by including microneedles, can obtain functional effects through transdermal absorption, and it has been shown that the present invention can provide an aerosol cosmetic composition with a high transdermal absorption promoting effect and a high blood flow promoting effect.

Claims

1. The undiluted solution containing microneedles, and A propellant containing at least carbon dioxide, an aerosol cosmetic containing, The aerosol cosmetic is filled into an aerosol container equipped with a dispensing mechanism for dispensing the aerosol cosmetic, The carbon dioxide concentration inside the aerosol container is 5,000 ppm or more. Aerosol cosmetics.

2. The aerosol cosmetic composition according to claim 1, wherein the viscosity of the undiluted solution at 25°C is 500 mPa·s or more.

3. The aerosol cosmetic composition according to claim 1 or 2, wherein the aerosol cosmetic composition is dispensed in the form of foam or drops.

Images